While some phase II studies have evaluated the use of bevacizumab in concert with interferon alpha 2B [11], [28], interferon alpha 2A [12] or chemotherapy [13], [14], to the best of our knowledge this is the first study evaluating bevacizumab monotherapy in metastatic malignant melanoma. The gene discussed is IFNA2; the disease is metastatic melanoma.